Marker Therapeutics
@markertherapeutics.com
We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s unique cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize multiple tumor associated antigens (multiTAA) and kill tumor cells expressing those targets. Once infused into patients, this population of multiTAA-specific T cells attacks multiple tumor targets and acts to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
Marker Therapeutics's Company Logos
Marker Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#015BD5
Science Blue
1, 91, 213
215, 99, 42
100, 57, 0, 16
#91D6C4
Vista Blue
145, 214, 196
164, 46, 70
32, 0, 8, 16
#004085
Congress Blue
0, 64, 133
211, 100, 26
100, 52, 0, 48
About Marker Therapeutics
Marker Therapeutics is a leading biotechnology company that specializes in developing innovative immunotherapies for the treatment of various cancers. With a strong focus on Multi TAA (Multiple Tumor-Associated Antigen) Therapies, Marker Therapeutics is committed to revolutionizing cancer treatment through its cutting-edge MTA technology. Marker Therapeutics offers a diverse pipeline of product candidates, backed by extensive scientific research and clinical trials.
The company's proprietary manufacturing processes ensure the production of high-quality and efficacious therapies. Their commitment to advancing the field of immunotherapy is evident through their numerous publications and active clinical trials. Investors and the media find comprehensive information about Marker Therapeutics on their user-friendly website.
The company provides timely updates on news, events, and financial data, including stock information. Marker Therapeutics is always on the lookout for talented individuals who share their passion for developing groundbreaking cancer therapies. If you are interested in joining the team, the Careers section of the website provides contact information for further inquiries.
For more information about Marker Therapeutics and its groundbreaking immunotherapies, please visit their headquarters in Houston, Texas, or contact them directly via phone
Company type
Public Company
Year founded
2018
Company size
11-50 employees
Related Brands
Tags
T-cell immunotherapy
Cell therapy manufacturing
Cancer clinical trials
Non-genetically engineered T cells
